Abbott Teams With Genentech, Roche, OSI On Lung Cancer Test
Friday, March 07, 2008; Posted: 09:54 PM

7 Stocks You Need To Know For Tomorrow -- Free Newsletter

(financialwire.net via COMTEX) -- OSIP | news | PowerRating | PR Charts

Free Report!

Double, Triple or Even Quadruple Your Returns Using ETFs

 

 

 

-- March 7, 2008 (FinancialWire) Abbott's (NYSE: ABT | news | PowerRating | PR Charts ) molecular diagnostics business has entered into an agreement with Genentech (NYSE: DNA), F. Hoffmann-La Roche and OSI Pharmaceuticals to develop a gene test to potentially assess the clinical benefit of Tarceva, an oral tablet used to treat advanced or metastatic non-small cell lung cancer.

Under the agreement, Abbott will develop a test to detect extra copies of the epidermal growth factor receptor gene using its proprietary fluorescence in situ hybridization technology in NSCLC. Financial terms of the deal were not disclosed.

Currently, there are no nucleic acid based tests validated or approved by the U.S. Food and Drug Administration that could identify patients who may derive greater treatment benefits from targeted lung cancer therapies.

Abbott Park, Illinois-based Abbott is a global health care company focused on the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 65,000 people and markets its products in more than 130 countries.

For up-to-the-minute news, features and links click on http://www.FinancialWire.net

FinancialWire is an independent, proprietary news service of Investrend Information, a division of Investrend Communications, Inc. It is not a press release service and receives no compensation from any company for its news or opinions. Other divisions of Investrend, however, provide shareholder empowerment platforms such as forums, independent research and webcasting. For more information or to receive the FirstAlert daily summary of news, commentary, research reports, webcasts, events and conference calls, click on http://www.investrend.com/contact.asp

For a free annual report on a company mentioned in the news, please click on http://investrend.ar.wilink.com/?level=279

To become an investor monitor of independent research for a company in which you are invested, go to the not-for-profit Shareholders Research Alliance, Inc. website by clicking on http://www.shareholdersresearch.com/

The FinancialWire NewsFeed is now available in multiple formats to your site or desktop, free. Click on: http://www.investrend.com/XmlFeeds?level=268

http://www.financialwire.net

Morning Coffee with TradingMarkets -- Free Newsletter

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index